Center Trials & Treatment – Glioblastoma Multiforme

Access Program Information

This is an expanded access program (EAP) for patient with Melanoma and Glioblastoma who have
progressed after prior Protocol therapy including Bevacizumab, Temozolomide ( TMZ ),
Ipilimumab, BRAF and MEK inhibitors. The patients whose tumors are EGFR, MET or ALK positive
should first receive an EFGR or ALK inhibitor, respectively, prior to treatment with

Rare Disease: